Analytical Data
-
Gene name
TNFSF10
- Application
-
Alternative Names
TNFSF10；APO2L；Tumor necrosis factor ligand superfamily member 10
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P50591
-
Expression Region
39-281aa
-
AA Sequence
TNELKQMQDKYSKSGIACFLKEDDSYWDPNDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG
-
Molecular Weight
32.4kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFSF10, also known as TRAIL (TNF-related apoptosis-inducing ligand), is a member of the tumor necrosis factor superfamily that plays a crucial role in regulating apoptosis, particularly in cancer cells. This protein can bind to specific receptors on the surface of target cells, triggering apoptotic pathways that lead to cell death, making it a significant focus of cancer research. Due to its selective cytotoxicity towards tumor cells while sparing normal cells, TNFSF10 has garnered attention as a promising therapeutic agent for cancer treatment. Research has focused on the recombinant production of TNFSF10 to enhance its stability, bioactivity, and therapeutic potential. Advances in recombinant DNA technology and expression systems enable the large-scale production of TNFSF10 for preclinical and clinical studies, allowing researchers to explore its efficacy when used alone or in combination with other therapies. Furthermore, understanding its mechanisms of action and resistance factors constitutes a vital area of investigation aimed at optimizing its clinical application. The ongoing studies also emphasize developing strategies to overcome potential resistance in cancer cells, thereby enhancing the effectiveness of TNFSF10-based therapies. Overall, the study of TNFSF10 as a recombinant protein represents a promising avenue in the quest for novel and effective anti-cancer treatments, highlighting its potential in precision medicine approaches.
